Realised by the University of Bologna and the UO of Romagna, in collaboration with the CRBA
The technology 'Fast and real-time electrical transistor assay for quantifying SARS-CoV-2 neutralising antibodies' - fast, effective, reliable and economical - developed to measure the level of neutralising antibodies against SARS-CoV-2 in the blood and also to test the efficacy of the new COVID vaccines, was presented in Communications Materials, a journal of the Nature group, and is the subject of a patent.
The device was developed by a research group led by scholars from the University of Bologna and the ASL of Romagna, among whom Dr Catia Giovannini, our collaborator since the foundation of the centre, who carried out much of the research at the CRBA.